No Data
Express News | Revive Therapeutics Ltd: Decided Not to Pursue Development of Long Covid Diagnostic Product
Express News | Revive Therapeutics Ltd - Additional Phase 3 Clinical Trial Data Analyses May Suggest Bucillamine's Potential for Long Covid.
Express News | Revive Therapeutics Ltd - FDA Has Recommended That Evaluation of Bucillamine for Long Covid Be Submitted as a New Ind Application
Express News | Revive Therapeutics Ltd - Company Is Exploring Use of Bucillamine as a Potential Treatment for Long Covid
Express News | Revive Therapeutics Ltd: Would Be Required to Conduct a Clinical Study for De Novo Submission for Possible Approval
Express News | Revive Therapeutics Ltd: FDA Has Determined That Product Should Follow De Novo Regulatory Pathway
No Data